Content area

|
|

Diagnostik og behandling af maturity onset diabetes of the young type 3

Forfatter(e)
Kathrine Rose1*, Alexander Sidelmann Christensen1*, Heidi Storgaard1, Sofie Hædersdal1, Torben Hansen3, Filip Krag Knop1, 2, 3 & Tina Vilsbøll1, 2, 4 1) Center for Diabetesforskning, Gentofte Hospital 2) Institut for Klinisk Medicin, Det Sundhedsvidenskabelige Fakultet, Københavns Universitet 3) Novo Nordisk Fondens Metabolismecenter, Panum Instituttet, Københavns Universitet 4) Steno Diabetes Center Copenhagen Ugeskr Læger 2018;180:V06170502
Reference: 
Ugeskr Læger 2017;179:V06170502
Blad nummer: 
Sidetal: 
2-6
Diagnosis and treatment of maturity onset diabetes of the young type 3
Maturity onset diabetes of the young type 3 (MODY3) is the most prevalent type of monogenetic diabetes. Treatment guidelines differ from both Type 1 diabetes and Type 2 diabetes. First-line treatment is a long-acting sulphonylurea, which lowers the plasma glucose level effectively, however with the risk of hypoglycaemia. When hypoglycaemia is a problem, short-acting sulphonylureas, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors may be used as alternatives. Metformin, glitazones and sodium glucose transporter 2-inhibitors have only limited applicability in MODY3. Further research needs to evaluate combinational therapy.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Camilla Bang | 16/10
1 Kommentar
af Tobias Ramm Eberlein | 15/10
6 kommentarer
af Frank Bang Nissen | 15/10
1 Kommentar
af Peter Hvidbak Revald | 14/10
3 kommentarer
af Arne Mejlhede | 11/10
1 Kommentar
af Sven Refslund Poulsen | 06/10
3 kommentarer